
1. vaccine. 2014 may 7;32(22):2599-603. doi: 10.1016/j.vaccine.2014.03.016. epub
2014 mar 21.

efficacy inactivated felv vaccine compared recombinant felv vaccine in
minimum age cats following virulent felv challenge.

stuke k(1), king v(2), southwick k(2), stoeva mi(2), thomas a(3), winkler mt(2).

author information: 
(1)zoetis, 20 mercuriusstraat, 1930 zaventem, belgium. electronic address:
kristin.stuke@zoetis.com.
(2)zoetis, 333 portage street, kalamazoo, mi 49007, usa.
(3)zoetis, 20 mercuriusstraat, 1930 zaventem, belgium.

comment in
    vaccine. 2015 jun 4;33(24):2737-8.
    vaccine. 2015 jun 4;33(24):2739-40.

the aim study determine efficacy inactivated feline
leukemia virus (felv) vaccine (versifel(®) felv, zoetis.) compared a
recombinant felv vaccine (purevax(®) felv, merial animal health) young cats,
exposed laboratory conditions highly virulent challenge model. the
study designed consistent general immunogenicity requirements 
of european pharmacopoeia 6.0 monograph 01/2008:1321-feline leukaemia vaccine
(inactivated) exception commercial-strength vaccines assessed.
fifty seronegative cats (8-9 weeks old) vaccinated subcutaneously two
occasions, three weeks apart, either placebo (treatment group t01), versifel
felv vaccine (treatment group t02), purevax felv vaccine (treatment group t03)
according manufacturer's directions. cats challenged three weeks
after second vaccination virulent felv isolate (61e strain).
persistent felv antigenemia determined 3 15 weeks postchallenge. bone
marrow samples tested presence felv proviral dna determine
felv latent infection. week 15 challenge virulent felv 61e
strain, versifel felv vaccine conferred 89.5% protection felv
persistent antigenemia 94.7% protection felv proviral dna integration
in bone marrow cells. comparison, purevax felv vaccine conferred 20%
protection felv persistent antigenemia 35% protection felv
proviral dna integration bone marrow cells following challenge. data 
this study show versifel felv vaccine efficacious preventing both
felv persistent p27 antigenemia felv proviral dna integration bone marrow 
cells cats challenged particular challenge model laboratory
conditions provided better protection purevax felv experimental 
challenge model highly virulent felv.

copyright © 2014 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2014.03.016 
pmid: 24662705  [indexed medline]

